
    
      The sponsors of this research also studied CD19.CAR-T cells for the treatment of leukemia and
      lymphoma, two courses of three transfusion 14 days after infection process standard training
      program , the safety and effectiveness have accumulated some of the data. In this study, the
      investigators will regenerate the cultured cells for 2 times in a course of treatment, and
      enter the patient's body . The investigators observed the safety and efficacy of CAR-T cell
      therapy.
    
  